“…Patients then underwent controlled ovarian hyperstimulation by luteal-phase gonadotropin-releasing hormone (GnRH) agonist, GnRH antagonist downregulation, or GnRH agonist flare protocol, with follicular synchronization and pituitary downregulation as clinically indicated and previously described [17,[19][20][21]. During treatment with recombinant gonadotropins (follitropin beta, Follistim, Merck, Kenilworth, NJ, or follitropin alpha, Gonal-F, EMD-Serono; and m e n o t r o p i n s , M e n o p u r o r R e p r o n e x , F e r r i n g Pharmaceuticals, Parsippany, NJ), patients were serially monitored with transvaginal ultrasound and serum estradiol (E 2 ) to assess follicular measurements and endometrial thickness.…”